Medscape Medical NewsAll articles

SubtlePET

Subtle Medical, Inc. • Radiology • 11/30/2018

510(k)IEC 62304 Class B
FDA Summary PDF

Device Purpose

SubtlePET is an advanced image processing software designed to enhance the diagnostic quality of PET scans by effectively reducing image noise using a deep learning algorithm. It employs a convolutional neural network with a residual learning approach to intelligently distinguish and suppress noise while preserving essential structural details in fluorodeoxyglucose (FDG) and amyloid PET images.

Summary

SubtlePET is an image processing software specifically designed for radiologists and nuclear medicine physicians to improve the quality of Positron Emission Tomography (PET) images. Its primary functions include the transfer, storage, and critically, the reduction of noise in fluorodeoxyglucose (FDG) and amyloid PET images, which encompasses modalities such as PET/CT and PET/MRI. The software aims to enhance these diagnostic images, making them clearer for clinical assessment by targeting noise that can obscure important details, and it is designed to integrate into existing radiology workflows by acting as a DICOM node for image transfer. The core technology behind SubtlePET's noise reduction capabilities is a deep neural network-based algorithm, specifically a convolutional neural network (CNN). This CNN operates by analyzing each pixel in the context of its neighborhood and employs a residual learning approach to predict and differentiate between noise components and actual structural information within the image. By separating these components, the software effectively enhances the underlying structures while simultaneously diminishing noise. Non-clinical performance testing, which included a noise reduction bench test utilizing representative human PET data, demonstrated a significant average increase in quantitative metrics, confirming the software's efficacy in reducing noise and improving image quality.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

SubtlePETImage ProcessingSoftwareNoise ReductionDeep Neural NetworkConvolutional Neural NetworkPETFDGAmyloid ImagingDICOM

Device Metadata

Submission Number
K182336
Company
Subtle Medical, Inc.
Panel
Radiology
Product Code
N/A
Data Type
Images
Clinical Function
Assessment
AI Function
Generation
AI Subclass
image enhancement

Relevant Clinical Questions

  • Q1. How does the residual learning approach in SubtlePET specifically differentiate between noise and structural components in PET images with varying levels of tracer uptake, anatomical complexity, and across different PET scanner models?; What were the specific quantitative metrics used in the noise reduction bench test for SubtlePET, and how do these metrics correlate with improvements in diagnostic accuracy, lesion detectability, or changes in clinical interpretation by radiologists and nuclear medicine physicians?; Are there specific types of PET artifacts (e.g., motion, truncation, scatter) or image characteristics (e.g., very low count studies) for which SubtlePET's noise reduction algorithm is less effective or might potentially introduce new, subtle artifacts?; What is the computational overhead and average processing time per study for SubtlePET, and how does its performance scale with increasing image matrix sizes or dataset volumes, particularly considering deployment on different IT infrastructures like on-site versus cloud-based virtual machines?; Beyond general noise reduction, does SubtlePET offer any customizable parameters for users to fine-tune the algorithm based on specific clinical questions, patient populations, or desired image characteristics (e.g., smoothness vs. sharpness)?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score15/100
SBOM Evidence⚠ Not mentioned in summary
Cyber Risk Assessment⚠ Not mentioned in summary
Postmarket Plan⚠ Not mentioned in summary
§524B ApplicableNo

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials
- Not detected
ML-BOMMachine Learning Bill of Materials(deep learning, neural network, algorithm, dataset)
✓ Detected
SaaSBOMSoftware-as-a-Service Bill of Materials(cloud, network, infrastructure)
✓ Detected
HBOMHardware Bill of Materials
- Not detected
CBOMCryptography Bill of Materials
- Not detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials(deployment)
✓ Detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of ML-BOM, SaaSBOM, OBOM detected in AI-generated device summary.

• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.

• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.

• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
SubtlePET - Subtle Medical, Inc. | ESL FDA AI Device Intelligence